Australian antiviral drug development company Island Pharmaceuticals has reallocated US government funding to support its planned ISLA-101 Phase 2a human clinical trial in dengue fever.
The Phase 2a trial will evaluate the effectiveness of Island’s lead asset, ISLA-101, against dengue fever when induced using a human challenge model. The company has reallocated almost $1 million from the $2 million grant it announced last year.
Island Pharmaceuticals CEO Dr David Foster said, “Thanks to our partners at SUNY [State University of New York] who have arranged this funding in consultation with the DoD [US Department of Defense]. We are most appreciative of this meaningful source of new, non-dilutive funding which sees Island’s own capital requirements for the study reduce markedly.
"As cases of dengue fever continue to spike around the globe, finding both preventatives and treatments are paramount. We are extremely hopeful about our potential to bring a new tool forward to combat the escalating dengue issue.”